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Abstract
Background: Variability in the management of glomerulonephritis may negatively impact efﬁcacy and safety. However, there
are little/no data on actual variability in the treatment of minimal change disease (MCD)/focal segmental glomerulosclerosis
(FSGS) in adults. We assessed Spanish practice patterns for themanagement of adult nephrotic syndrome due to MCD or FSGS.
The absence of reasonably good evidence on treatment for a disease often increases the variability substantially. Identiﬁcation
of evidence–practice gaps is the ﬁrst necessary step in the knowledge-to-action cyclical process. We aim to analyse the real
clinical practice in adults in hospitals in Spain and compare this with the recently released Kidney Disease: Improving Global
Outcomes clinical practice guideline for glomerulonephritis.
Methods: Participating centreswere required to include all adult patients (age >18 years)with a biopsy-provendiagnosis ofMCD
or FSGS from 2007 to 2011. Exclusion criteria included the diagnosis of secondary nephropathy.
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Results: Westudied 119 Caucasian patientswith biopsy-provenMCD (n = 71) or FSGS (n = 48) from13 Spanish hospitals. Of these
patients, 102 received immunosuppressive treatment and 17 conservative treatment. The initial treatmentwas steroids, except
in onepatient inwhichmycophenolatemofetilwas used. In all patients, the steroidswere given as a single daily dose. Themean
duration of steroid treatment at initial high doses was 8.7 ± 13.2 weeks and the mean global duration was 38 ± 32 weeks. The
duration of initial high-dose steroidswas <4weeks in 41%of patients and >16weeks in 10.5%of patients.We did ﬁnd aweak and
negative correlation between the duration of whole steroid treatment in the ﬁrst episode and the number of the later relapses
(r =−0.24, P = 0.023). There were 98 relapses and they were more frequent in MCD than in FSGs patients (2.10 ± 1.6 versus
1.56 ± 1.2; P = 0.09). The chosen treatment was mainly steroids (95%). Only seven relapses were treated with another drug as a
ﬁrst-line treatment: two relapses were treated with mycophenolate and ﬁve relapses were treated with anticalcineurinics. A
second-line treatment was needed in 29 patients (24.4%), and the most frequent drugs were the calcineurin inhibitors (55%),
followed bymycophenolatemofetil (31%). Although cyclophosphamide is the recommended treatment, it was used in only 14%
of the patients.
Conclusions: We found variation from the guidelines in the duration of initial and tapered steroid therapy, in the medical
criteria for classifying a steroid-resistant condition and in the chosen treatment for the second-line treatment. All nephrologists
started with a daily dose of steroids as the ﬁrst-line treatment. The most frequently used steroid-sparing drug was calcineurin
inhibitors. Cyclophosphamide use was much lower than expected.
Key words: clinical practice variability, glomerulonephritis, immunosuppression
Introduction
Variability in the management of glomerulonephritis could
negatively impact efﬁcacy and safety, increasing the risk of
progression to end-stage renal disease [1]. More than 75% of Can-
adian IgA nephropathy patients have proteinuria >1 g/day and
GFR >50 mL/min/1.73 m2, yet only 33% received steroid treatment
despite evidence suggesting this would improve renal outcome
[2–4]. Furthermore, 19% of patients with membranous nephro-
pathy and subnephrotic proteinuria are treated with immuno-
suppression in spite of a good long-term renal outcome with
renin–angiotensin system blockade [5]. Currently, there is little
information on variability of clinical practice for the manage-
ment of adult nephrotic syndrome due to minimal change dis-
ease (MCD) or focal segmental glomerulosclerosis (FSGS), which
are considered rare diseases. Two nephrologist-level surveys
have been published in the last 16 years, one on paediatric ster-
oid-resistant FSGS patients and the other on overall glomerulo-
nephritis management, both presenting only North America
data [6, 7]. Only one study has assessed the homogeneity of treat-
ment in adults [8], but it did not provide patient-level data, and
gaps may exist between what nephrologists plan to do and
what they actually do.
The Kidney Disease: Improving Global Outcomes (KDIGO)
clinical practice guideline for glomerulonephritis presents an ex-
cellent summary of the current state of knowledge on glomerular
disease management and thus provides a useful framework for
the clinician [9].
Childhood nephrotic syndrome is one of the most common
childhood kidney diseases, affecting ∼16 per 100 000 children
[10]. More than 90% of cases are due to MCD or FSGS. Nephrotic
syndrome incidence is lower in adults than in children, and
MCD and FSGS account for only 25–30% of adult nephrotic syn-
drome cases. There are scarce randomizedclinical trials (RCTs) ad-
dressing therapy for these conditions [11]. As a consequence,most
recommendations for the treatment of adult nephrotic syndrome
are based largely on extrapolation fromchildhood studies, and the
quality of evidence is low (‘the true effectmay be substantially dif-
ferent from the estimate of the effect’) or very low (‘the estimate of
effect is very uncertain, and often will be far from the truth’).
Under these circumstances, implementation of guidelines
may be compromised if recommendations differ much from
usual clinical practice. We aimed to assess Spanish practice pat-
terns for the management of adult nephrotic syndrome due to
MCD or FSGS, as a country representative of a public universal
health care system, and to compare these with recommenda-
tions from the KDIGO clinical practice guideline for glomerulone-
phritis [9].
Methods
Study population and patient selection
We enrolled patients with a renal biopsy diagnosis of MCD or
FSGS from 2007 to 2011 in 13 Spanish hospitals belonging to the
Spanish group for the study of glomerular diseases (GLOSEN).
Clinical records were retrospectively reviewed. Renal biopsies
were processed for light microscopy, immunoﬂuorescence and
electron microscopy. Patients younger than 18 years at the time
of the biopsy, with any cause of secondary forms or who had re-
ceived immunosuppressive treatment prior to renal biopsy were
excluded. Demographics, baseline characteristics, kind and
length of treatment at the beginning and in relapses, frequency
and timing of relapses, complications, outcome data and labora-
tory parameters were recorded.
Deﬁnitions
Complete remissionwas deﬁned as a daily urine protein excretion
<0.3 g/day, urine protein∶creatinine ratio <0.3 g/g, normal serum
creatinine and serum albumin >3.5 g/dL. Partial remission was de-
ﬁned as proteinuria reduction ≥50% from the baseline value with
absolute proteinuria 0.3–3.5 g/day (urine protein∶creatinine ratio
0.3–3.5 g/g) and stable serum creatinine (change in creatinine
<25%). Frequent relapse was deﬁned as two or more relapses
within 6 months of initial response or four or more relapses in
any 12-months period. Steroid dependence was deﬁned as two
consecutive relapses during steroid therapy. Steroid resistance
was deﬁned as persistence of proteinuria despite prednisone
1mg/kg/day or 2 mg/kg every other day for >4 months.
Statistical analyses
Baseline characteristics are expressed as mean ± standard devi-
ation (SD) ormedian and interquartile range (IQR) for continuous
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variables and percentage for categorical variables. Data between
groups were compared by χ2 test, paired t-test, one-way analysis
of variance or Mann–Whitney U test, as appropriate. Statistics
were calculated using SPSS for Windows, version 11 (SPSS,
Chicago, IL, USA).
Results
We studied 119 adult patients with biopsy-proven MCD (71 pa-
tients) or FSGS (48 patients) from 13 GLOSEN hospitals. Baseline
characteristics are shown in Table 1. Serum albumin and the
number of sclerotic glomeruli were signiﬁcantly lower in MCD
than in FSGS patients (2.10 ± 0.65 versus 2.82 ± 0.99 g/dL and 4.94
± 10.04 versus 18.20 ± 19.32; P < 0.0001, respectively).
Of the 119 patients, 102 (82%) received steroids or immuno-
suppressive treatment (calcineurin inhibitors, mycophenolate
mofetil or cyclophosphamide; active treatment group) and 17
received conservative treatment. Six of the 102 patients who
received active treatment had proteinuria <3.5 g/day and serum
albumin >3.5 g/dL. Two of the 17 patients on conservative treat-
ment had proteinuria >3.5 g/day and serum albumin <3.5 g/dL,
the rest not having nephrotic syndrome.
Median follow-up was 44 (IQR 22–56) months. At the end
of follow-up, 3 (2.5%) patients had died, 20 (16.8%) were lost to
follow-up, 71 (59.7%) attained complete remission, 18 (15.1%)
achieved partial remission and 7 (5.9%) maintained nephrotic
syndrome.
Initial therapy for the ﬁrst episode
Almost all (101 of the 102) active treatment patients re-
ceived steroids as ﬁrst-line treatment. One FSGS patient initially
received mycophenolate. The mean initial steroid dose was 63 ±
16 mg/day (0.89 ± 0.13 mg/kg/day) in MCD patients and 63.7 ±
11.79 (0.85 ± 0.14 mg/kg/day) in FSGS patients (ns).
The mean duration of steroids at initial high doses was
8.7 ± 13.2weeks (median 5, IQR 3–9) and themean global duration
of steroid treatment was 38 ± 32 weeks (median 26, IQR 17–45).
The mean duration of initial high-dose steroids was less for
MCD than for FSGS patients (5.7 ± 3.5 versus 13.0 ± 19.4weeks, P =
0.024). The entire steroid treatment duration was also signiﬁcant-
ly shorter for MCD than for FSGS patients (24.7 ± 20.7 versus
55.6 ± 39.4 weeks; P < 0.0001).
The duration of initial high-dose steroidswas <4weeks in 41%
of patients (43% in MCD and 37.5% in FSGS; P = 0.548, NS), 4–8
weeks in 32.6% (40% in MCD versus 22.5% in FSGS; P = 0.017),
8–12 weeks in 8.4% (11% in MCD versus 5% in FSGS; P < 0.001),
12–16 weeks in 7.4% (5.4% in MCD versus 10% in FSGS; P < 0.0001)
and >16 weeks in 10.5% of patients, all of them having FSGS (25%
of FSGS patients).
Of the 102 active treatment patients, 21 were deﬁned as ster-
oid dependent [17/62 (27.4%)MCD, 4/40 (10%) FSGS; P = 0.03], 26 as
steroid resistant [6/62 (9.6%) MCD, 20/40 (50%) FSGS; P < 0.0001,
ns] and 55 responded to steroids [39/62 (63%) MCD versus 16/40
FSGS (40%) FSGS; P < 0.002].
The total duration of steroid treatment was longer in steroid-
resistant (60.1 ± 36.2 weeks) than in steroid-dependent pa-
tients (28.7 ± 25.7 weeks) or responder patients (29.4 ± 27.7
weeks) (P < 0.0001) and we found no difference in high-dose
length (9.5 ± 11.8 weeks in steroid dependent, 7.3 ± 5.0 weeks
in steroid sensitive and 8.8 ± 15.8 weeks in steroid resistant; P =
0.86). In the steroid-resistant group (n = 26), 7 patients received
steroids for <4 weeks and 6 patients for <8 weeks (Figure 1).
A negative correlation was found between the full duration of
steroid treatment in the ﬁrst episode and the number of later re-
lapses (r =−0.24, P = 0.023). The average number of relapses was
similar in patients who received steroids for 4 versus 4 weeks
(1.95 ± 1.60 versus 1.88 ± 1.42). At the end of follow-up, patients
who had attained complete remission had received steroid treat-
ment for a shorter period in the ﬁrst episode (33.9 ± 32 weeks)
than patients in partial remission (64.6 ± 28.1 weeks; P = 0.012)
or non-responder patients (46.2 ± 62.8 weeks; P = 0.024).
Second-line treatment for the ﬁrst episode
A second-line treatment was prescribed for the ﬁrst episode in
29 patients (24.4%): calcineurin inhibitors [n = 16 (55%)], myco-
phenolate [n = 7 (31%)] and cyclophosphamide [n = 4 (14%)].
This distribution was similar in steroid-dependent and in
steroid-resistant patients. Indications for second-line treatment
Table 1. Baseline clinical characteristics of 126 patients included in the study
Total MCD FSGS P-value
Age (years) 47.98 ± 19.85 50.54 ± 20.13 44.34 ± 19.06 ns
BMI (kg/m2) 26.85 ± 5.38 26.48 ± 4.85 27.32 ± 6.10 ns
Serum creatinine (μmol/L) 114.9 ± 70.7 109.6 ± 76.9 121.1 ± 61.8 ns
Proteinuria (g/24 h) 7.98 ± 6.73 8.71 ± 7.27 6.97 ± 5.83 ns
UPCR (mg/g) 4876 ± 3607 4454 ± 2963 5453 ± 4359 ns
Albumin (g/dL) 2.44 ± 0.90 2.10 ± 0.65 2.82 ± 0.99 0.0001
Number of relapses 1.75 ± 1.44 1.96 ± 1.62 1.45 ± 1.08 0.038
Number of glomeruli 15.05 ± 8.38 14.97 ± 8.98 15.08 ± 7.89 ns
Sclerotic glomeruli (%) 7.36 ± 13.42 4.94 ± 10.04 18.20 ± 19.32 0.0001
UPCR, urinary protein∶creatinine ratio.
Fig. 1. Duration of high-dose steroids according to response.
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included steroid resistance or dependence, partial response to
steroids, frequent relapses and toxicity or contraindications to
steroids. Some patients received more than one agent (usually
sequentially).
Initial therapy in relapses
There were 98 relapses and they tended to be more frequent in
MCD than in FSGS patients (2.10 ± 1.6 versus 1.56 ± 1.2 relapses;
P = 0.09) (Figure 2).
Relapses were treated initially with steroids in 91 patients
(95%). Only seven relapses were treated initially with another
drug: two with mycophenolate and ﬁve with calcineurin inhibi-
tors (Figure 3).
The average initial dose of steroids was signiﬁcantly lower in
each successive relapse: the average dose was 55.79 ± 18.34 mg/
day in the ﬁrst treatment, 55.7 ± 18.3 mg/day in the ﬁrst relapse,
52.5 ± 17.9 mg/day in the second relapse, 47.0 ± 20.5 mg/day
in the third relapse and 42.8 ± 19.7 mg/day in the fourth relapse
(P < 0.0001). There was no difference in the duration of steroid
treatment between the relapses.
Second-line treatment in relapses
Calcineurin inhibitors were more frequently used in relapses.
Thus, they were the second-line treatment in 81% of patients in
the ﬁrst relapse and in 77.7% of patients in the second relapse.
Discussion
Although there is some uniformity, signiﬁcant practice variabil-
ity does exist in the management of adult idiopathic nephrotic
syndrome,MCD and FSGS in Spain. Our study demonstrated vari-
ability in criteria for starting treatment, in duration of initial and
tapered off steroid regimens, in medical criteria for classifying
the steroid-resistant condition and in the second-line treatment.
Nephrotic syndrome secondary toMCD is associatedwith sig-
niﬁcant morbidity due to accelerated atherosclerosis, due in part
to dyslipidemia [12], infections [13, 14] and thromboembolic
events [15]. Patients with FSGS and persistent nephrotic syn-
drome are at increased risk of progressive CKD and its accom-
panying cardiovascular morbidity and mortality. Risks are
dependent on the level of proteinuria and kidney function, so pa-
tients with non-nephrotic proteinuria have a good prognosis,
with kidney survival rates of >95% after a mean follow-up of
6.5–9.3 years [7, 16], even in older studies. Hence, the KDIGO
guideline recommends steroids and immunosuppressive ther-
apy only in idiopathic nephrotic syndrome and not in patients
with subnephrotic proteinuria. In our study, six patients received
immunosuppressive treatment, although they only had subne-
phrotic proteinuria. In a Canadian survey, 9% of nephrologists
would not prescribe immunosuppressive therapy to patients
with FSGS and proteinuria >5 g/day and, conversely, 26% of
nephrologists would treat FSGS and proteinuria of 2 g/day with
prednisone or calcineurin inhibitor [6].
The overall grade of evidence to guide treatment of these dis-
eases is based on and extrapolated from studies in children. The
current KDIGO guideline suggests that the initial high dose of
steroids should bemaintained for a minimum of 4 weeks if com-
plete remission is achieved and for a maximum of 16 weeks if
complete remission is not attained. Steroids should be tapered
slowly over a total period of up to 6months after achieving remis-
sion [9]. There is some consensus that adults respondmore slow-
ly to therapy than children and they should not be considered to
be steroid resistant until after 16 weeks of therapy. However,
these timelines are arbitrary. A recent systematic review of the
Cochrane Central Register of Controlled Trials, Medline and Em-
base reference articles and abstracts from conference proceed-
ings for RCTs or quasi-RCTs identiﬁed only three RCTs with 68
participants >18 years of age. These data proved inadequate to
draw any ﬁrm conclusions with respect to the utility or duration
of prednisone therapy in adults. Nonetheless, in spite of the se-
vere paucity of RCT data, other nephrology societies, such as
the Canadian Society of Nephrology, agreed with the general
principles of management proposed by the KDIGO guideline [17].
Using these guidelines as a comparison, Spanish nephrolo-
gists appear to be prescribing high-dose steroids for less time
than recommended in the guideline but keep a similar duration
of the tapering period. Treatment length variability was also
found in a Canadian and North American practice variation
study in children [1, 18].
In our study, nearly half of patients (41%) were treated with
high steroid doses for less time than recommended in most
guidelines (<16 weeks). The shorter duration was not associated
with a higher number of subsequent relapses or with requiring
second-line treatment.
In fact, the percentage of steroid-resistant patients in MCD
(9.6%) was similar [13, 19–21] or even lower than in previous re-
ports [22, 23]. In our study, the global steroid treatment was
long (38 ± 32 weeks), and this may explain the good outcome. In
a meta-analysis of published studies in childhood MCD, a longer
course of initial steroid treatment (lower dose for longer time)
was associated with a lower relapse rate [24]. We questioned
whether it is necessary to maintain high-dose steroids for up to
16weeks if a complete remission is not attained, given the poten-
tial formajor side effects. In this regard, the addition of three new
Fig. 3. First-line treatment in the ﬁrst episode and in relapses.
Fig. 2. Number of relapses.
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well-designed studies has changed previous Cochrane Collabor-
ation conclusions on steroid treatment duration in children [24].
There was no signiﬁcant difference in the risk of steroid depend-
ence between prednisone for 8–12 weeks and longer duration or
total dose of therapy, indicating that there is no beneﬁt of in-
creasing the duration of high-dose prednisone beyond 8–12
weeks in the initial episode.
The KDIGO guideline [9] recommends alkylating agents for
steroid-dependent patients and suggests calcineurin inhibitors
only for patients with relapse despite cyclophosphamide and
for those who wish to preserve fertility [9]. This suggestion is
based on studies that show that both drugs lead to remission in
a signiﬁcant number of adults [25–27], but the relapse-free inter-
val appears to be longer with cyclophosphamide.
For steroid-resistant nephrotic syndrome, mainly FSGS pa-
tients, calcineurin inhibitors are suggested based on several stud-
ies [28–30]. The study byGullatti et al. [29] compared tacrolimus for
12 months or 6 monthly infusion of intravenous cyclophospha-
mide, with both arms receiving equal amounts of alternate-day
prednisolone. Complete remission was signiﬁcantly higher with
tacrolimus (52.4%) than with cyclophosphamide (14.8%).
In our study, the use of cyclophosphamide was the exception
not the rule. Calcineurin inhibitors were the most commonly
used drugs in steroid-dependent or steroid-resistant patients.
In a Canadian variability study, there was uniformity in the use
of an alkylating agent (cyclophosphamide) as a steroid-sparing
therapy in children with biopsy-proven MCD and calcineurin in-
hibitors to reduce steroid exposure in childrenwith FSGS. Despite
a lack of evidence that kidney biopsy results infer the success for
a speciﬁc therapy or disease outcome in steroid-dependent or
steroid-resistant patients, in the Canadian study, histopatho-
logical ﬁndings appeared to inﬂuence treatment choices [1].
The Cochrane group identiﬁed no RCTs comparing regimens
in adults with steroid-dependent or relapsing disease or compar-
ing treatment regimens comprising alkylating agents, cyclospor-
ine, tacrolimus, levamisole or mycophenolate mofetil [11].
The KDIGO guideline’s preface states the primary goal of the
guideline is ‘to improve quality of care . . . by helping clinicians
know and better understand the evidence (or lack of evidence)
that determines practice’. However, there is a strong body of lit-
erature suggesting that despite the presence of reasonably good
evidence on treatment for a disease, current clinical practice
often substantially deviates from the evidence [6]. In the present
Spanish study, adherence to guidelines was higher for recom-
mendations supported by good evidence, for instance, the use
of steroids as ﬁrst-line treatment, and has been more chaotic
for other recommendations based on lower-quality evidence,
e.g. the duration of steroid treatment and second-line treatment
in patients with steroid dependence or steroid resistance.
Spain is a country with universal health care access and in-
surance coverage for immunosuppressive medications. There-
fore, the observed variability would not be linked to poor access
to medical care or immunosuppressive drugs.
Most (95%) recommendations for the management of MCD
and FSGS in adults are Grade ‘C’ or lower and three recommen-
dations are not graded. Systematic reviews usually conclude
that new RCTs should be carried out and that extrapolation of
the paediatric literature should be avoided, but the state of the
art has not changed in recent decades.
These are orphan diseases, and the limited number of new
cases seen yearly by individual nephrologists causes variability
and limits our ability to advance therapy. Reference centres
should be instituted that either care for these patients or provide
and monitor advice to individual nephrologists. This kind of
structure would allow the implementation of prospective homo-
geneous protocols with frequent assessment of results and facili-
tate enrolling patients in RCTs.
There are several limitations in our study design. The studied
period preceded the KDIGO glomerulonephritis guideline publi-
cation in 2012. Thus, these results should not be interpreted as
a failure of guideline implementation, but instead highlight the
variability in practice patterns and current care gaps linked to lit-
erature evidence at that moment. On the other hand, most par-
ticipant centres (but not all) are academic hospitals, so it is
possible that regional hospitals present a different spectrum of
variability. Finally, in some clinical scenarios (e.g. adverse reac-
tions to drugs, unacceptable cosmetic side effects), deviations
from published guidelines and therapy individualization are en-
tirely justiﬁed, and we do not consider these particular situa-
tions. We should not forget that these diseases can affect old
and very old patients. In the Spanish glomerular disease registry,
13.4 and 8.2% of renal biopsies in patients >65 years of age with
nephrotic syndrome were diagnosed as MCD and FSGS, respect-
ively. Intolerance to steroid or other immunosuppressive therapy
tends to be more signiﬁcant and severe in the presence of ad-
vanced age and other comorbid conditions, such as obesity and
diabetes. Even evidence supported by good quality data may
not suit an individual patient.
In summary,wehave documented signiﬁcant clinical practice
variability and evidence of practice gaps in the management of
adult nephrotic syndrome in Spain. Clinical practice variability
is higher in items supported by low (Grade C) or very low grade
evidence (Grade D or not graded). The high clinical practice vari-
ability and low-quality evidence to support recommendations
argue for the establishment of reference centres where patients
with these rare diseases can be treated following homogeneous
protocols and enrolled in RCTs.
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